https://orcid.org/0000-0002-7464-8008
Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Ranjit Kumar Mahato, Mohini Singh, Hemanta Pathak, Niva Rani Gogoi, Rikynjai Kharbithai, Pinky Chowrasia, Pankaj Lochan Bora, Tumpa Sarkar, Bani Kumar Jana & Bhaskar Mazumder. (2023) Emerging Nanotechnology Backed Formulations for the Management of Atopic Dermatitis. Therapeutic Delivery 14:9, pages 543-569.
Read now
Read now
Articles from other publishers (23)
Jun-Hong TsaiTsen-Fang Tsai. (2024) A Review of Dupilumab-Induced Adverse Events to Dermatologists and the Potential Pathogenesis in the Treatment of Atopic Dermatitis. Dermatitis® 35:1, pages 24-42.
Crossref
Crossref
Kripa Ahuja & Peter Lio. 2024. Clinical Cases in Atopic Dermatitis. Clinical Cases in Atopic Dermatitis
107
120
.
Austin R. Swisher, Rijul S. Kshirsagar, Priscilla Q. VuJonathan Liang. (2023) Ocular Surface Adverse Events are not Associated with Dupilumab use in Nasal Polyp Treatment. The Laryngoscope.
Crossref
Crossref
Sayali Prakash Pradhan, Salman Naveed Sadiq, Cristian Cartes, Parastoo Babakinejad, Stephanie Ball, Nick J Reynolds, Simon Meggitt & Francisco C Figueiredo. (2023) Dupilumab induced ocular surface disease: A prospective case series. European Journal of Ophthalmology.
Crossref
Crossref
Duoduo Wu, Benjamin S. Daniel, Andre J.X. Lai, Nathan Wong, Dawn K.A. Lim, Dedee F. Murrell, Blanche X.H. Lim, Jodhbir S. Mehta & Chris H.L. Lim. (2022) Dupilumab-associated ocular manifestations: A review of clinical presentations and management. Survey of Ophthalmology 67:5, pages 1419-1442.
Crossref
Crossref
Sabrina Mukhtar & Vishal Jhanji. (2022) Effects of systemic targeted immunosuppressive therapy on ocular surface. Current Opinion in Ophthalmology.
Crossref
Crossref
N. Neagu, C. Dianzani, G. Avallone, C. Dell’Aquila, S.‐H. Morariu, I. Zalaudek & C. Conforti. (2022) Dupilumab ocular side effects in patients with atopic dermatitis: a systematic review. Journal of the European Academy of Dermatology and Venereology 36:6, pages 820-835.
Crossref
Crossref
Anna Kychygina, Myriam Cassagne, Marie Tauber, Stéphane Galiacy, Carle Paul, Pierre Fournié & Michel Simon. (2022) Dupilumab-Associated Adverse Events During Treatment of Allergic Diseases. Clinical Reviews in Allergy & Immunology 62:3, pages 519-533.
Crossref
Crossref
Michael J. Murphy, Jeffrey M. Cohen, Matthew D. Vesely & William Damsky. (2022) Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis. Journal of the American Academy of Dermatology 86:5, pages 1080-1091.
Crossref
Crossref
Magdalena Z. Popiela, Ramez Barbara, Andrew M. J. Turnbull, Emma Corden, Beatriz Suarez Martinez-Falero, Daniel O’Driscoll, Michael R. Ardern-Jones & Parwez N. Hossain. (2021) Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae. Eye 35:12, pages 3277-3284.
Crossref
Crossref
Masahiro Kamata & Yayoi Tada. (2021) A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis. JID Innovations 1:3, pages 100042.
Crossref
Crossref
Sunny Park, Jung Hyun Lee, Ji Hyun Park, So Hyang Park, Song Yi Park, Yong Woo Jung & Soo An Choi. (2021) Ocular surface disorders associated with the use of dupilumab based on WHO VigiBase. Scientific Reports 11:1.
Crossref
Crossref
Christine E. Jo, Asfandyar Mufti, Muskaan Sachdeva, Melanie Pratt & Jensen Yeung. (2021) Effect of dupilumab on allergic contact dermatitis and patch testing. Journal of the American Academy of Dermatology 84:6, pages 1772-1776.
Crossref
Crossref
Christine E. Jo, Alexandra Finstad, Jorge R. Georgakopoulos, Vincent Piguet, Jensen Yeung & Aaron M. Drucker. (2021) Facial and neck erythema associated with dupilumab treatment: A systematic review. Journal of the American Academy of Dermatology 84:5, pages 1339-1347.
Crossref
Crossref
A.T. Touhouche, M. Cassagne, E. Bérard, F. Giordano‐Labadie, A. Didier, P. Fournié, C. Paul & M. Tauber. (2020) Incidence and risk factors for dupilumab associated ocular adverse events: a real‐life prospective study. Journal of the European Academy of Dermatology and Venereology 35:1, pages 172-179.
Crossref
Crossref
Canan Asli Utine, Gavin Li, Penny Asbell, Stephen Pflugfelder & Esen Akpek. (2021) Ocular surface disease associated with dupilumab treatment for atopic diseases. The Ocular Surface 19, pages 151-156.
Crossref
Crossref
Gavin Li, Meghan Berkenstock & Uri Soiberman. (2020) Corneal ulceration associated with dupilumab use in a patient with atopic dermatitis. American Journal of Ophthalmology Case Reports 19, pages 100848.
Crossref
Crossref
Tatjana Honstein & Thomas Werfel. (2020) The show must go on: an update on clinical experiences and clinical studies on novel pharmaceutical developments for the treatment of atopic dermatitis. Current Opinion in Allergy & Clinical Immunology 20:4, pages 386-394.
Crossref
Crossref
Paulina LibermanAmde Selassie Shifera & Meghan Berkenstock. (2020) Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis. Cornea 39:6, pages 784-786.
Crossref
Crossref
Joanna Jaros, Aleksi J. Hendricks, Vivian Y. Shi & Peter A. Lio. (2020) A Practical Approach to Recalcitrant Face and Neck Dermatitis in Atopic Dermatitis. Dermatitis 31:3, pages 169-177.
Crossref
Crossref
. (2019) Dupilumab. Reactions Weekly 1781:1, pages 153-153.
Crossref
Crossref
Adrien Maudinet, Sandrine Law-Koune, Claire Duretz, Audrey Lasek, Philippe Modiano & Thi Ha Chau Tran. (2019) Ocular Surface Diseases Induced by Dupilumab in Severe Atopic Dermatitis. Ophthalmology and Therapy 8:3, pages 485-490.
Crossref
Crossref
Alison D. Treister, Cheryl Kraff-Cooper & Peter A. Lio. (2019) Learning About Dupilumab-Associated Conjunctivitis—Reply. JAMA Dermatology 155:6, pages 754.
Crossref
Crossref